These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27165260)

  • 1. Stopping guidelines for an effectiveness trial: what should the protocol specify?
    Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A
    Trials; 2016 May; 17(1):240. PubMed ID: 27165260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reporting on data monitoring committees in neonatal randomised controlled trials is inconsistent.
    Perrem LM; Gosling S; Ravikumar I; Khashan AS; Miletin J; Ryan CA; Dempsey E
    Acta Paediatr; 2017 Jan; 106(1):30-33. PubMed ID: 27637413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
    Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
    Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When is it safe to stop for safety?
    Schulman S; Carlsson A; Laporte S
    J Thromb Haemost; 2012 Jun; 10(6):1188-90. PubMed ID: 22486929
    [No Abstract]   [Full Text] [Related]  

  • 9. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early stopping rules in oncology: considerations for clinicians.
    Mukherjee SD; Goffin JR; Taylor V; Anderson KK; Pond GR
    Eur J Cancer; 2011 Nov; 47(16):2381-6. PubMed ID: 21684153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands.
    van den Bogert CA; Souverein PC; Brekelmans CTM; Janssen SWJ; Koëter GH; Leufkens HGM; Bouter LM
    J Clin Epidemiol; 2017 Aug; 88():140-147. PubMed ID: 28487159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When enough is enough: how the decision was made to stop the FEAST trial: data and safety monitoring in an African trial of Fluid Expansion As Supportive Therapy (FEAST) for critically ill children.
    Todd J; Heyderman RS; Musoke P; Peto T
    Trials; 2013 Mar; 14():85. PubMed ID: 23531379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Bayesian early stopping boundaries for phase II clinical trials.
    Jiang L; Yan F; Thall PF; Huang X
    Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Part 1: Ethical considerations.
    Ball G; Piller LB; Silverman MH
    Contemp Clin Trials; 2011 Sep; 32 Suppl 1():S2-4. PubMed ID: 21664987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.